• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer.

作者信息

Kwan Edmond M, Azad Arun A

机构信息

Department of Medicine, School of Clinical Sciences, Monash University.

Department of Medical Oncology, Monash Health.

出版信息

Curr Opin Urol. 2020 Jul;30(4):617-619. doi: 10.1097/MOU.0000000000000777.

DOI:10.1097/MOU.0000000000000777
PMID:32452996
Abstract
摘要

相似文献

1
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer.对于转移性激素敏感性前列腺癌，应首选化疗而非雄激素受体靶向治疗。正方观点：多西他赛化疗应作为转移性激素敏感性前列腺癌的默认治疗方案。
Curr Opin Urol. 2020 Jul;30(4):617-619. doi: 10.1097/MOU.0000000000000777.
2
[Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].[化疗联合雄激素剥夺疗法治疗高负荷转移性激素敏感性前列腺癌：短期疗效与安全性分析]
Zhonghua Wai Ke Za Zhi. 2019 Jun 1;57(6):418-421. doi: 10.3760/cma.j.issn.0529-5815.2019.06.005.
3
[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].
Urologe A. 2020 Jun;59(6):723-724. doi: 10.1007/s00120-020-01176-y.
4
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.多西他赛联合雄激素剥夺疗法用于激素敏感性转移性前列腺癌患者：一项系统评价与荟萃分析
Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28.
5
Role of chemotherapy in prostate cancer.化疗在前列腺癌中的作用。
Asian J Androl. 2018 May-Jun;20(3):221-229. doi: 10.4103/aja.aja_40_17.
6
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.对于 70 岁以上激素敏感性晚期前列腺癌患者的初始治疗中，加用多西他赛、阿比特龙、塞来昔布或唑来膦酸是否有益？一项荟萃分析。
Clin Genitourin Cancer. 2019 Aug;17(4):e806-e813. doi: 10.1016/j.clgc.2019.05.001. Epub 2019 May 13.
7
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].多西他赛或阿比特龙联合雄激素剥夺疗法治疗转移性前列腺癌
Urologe A. 2019 Oct;58(10):1185-1197. doi: 10.1007/s00120-019-0953-y.
8
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
9
The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
Anticancer Agents Med Chem. 2016;16(9):1166-71. doi: 10.2174/1871520616666160121113558.
10
Taxane-based Combination Therapies for Metastatic Prostate Cancer.基于紫杉烷的联合治疗转移性前列腺癌。
Eur Urol Focus. 2019 May;5(3):369-380. doi: 10.1016/j.euf.2017.11.009. Epub 2017 Dec 21.